Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma

Figure 2

Pretreatment plasma concentrations of VEGF (a) and PlGF (b) are shown according to sarcoma subtype. Pretreatment VEGF concentrations were highest in the patient with angiosarcoma.

(a)

(b)